Edurant (Rilpivirine HCl) Patent Expiration, LOE Window & CMS Spending

Edurant (Rilpivirine HCl) by Johnson & Johnson: FDA Orange Book LOE 2027-09-15, 2 AB generics, $32.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN202022 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-09-15
Orange Book Patents (*PED Extensions)0 patents (1 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$32.2M
2024 Medicare Part D Spend$23.9M
2024 Medicaid Spend$8.3M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 21.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.